Pfizer (PFE) and BioNTech SE Announce Positive Topline Results From an Ongoing Phase 3 Clinical Trial

Pfizer Inc. (NYSE:PFE) is one of the best growth stocks under $50 to buy now. On September 8, Pfizer Inc. (NYSE:PFE) and BioNTech SE announced positive topline results from an ongoing Phase 3 clinical trial cohort “evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY® 2025-2026 Formula in adults aged 65 and older and in adults aged 18 through 64 with at least one underlying risk condition for severe COVID-19.” Pfizer’s (PFE) Breakthrough Medici ...